Impact of ABCG2 Polymorphisms on the Clinical Outcome and Toxicity of Gefitinib in Non-Small-Cell Lung Cancer Patients

• Assaraf YG : The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.Drug Resist. Updat.9 , 227–246 (2006).
   PubMed Web of Science ®Google Scholar
• Robey RW , PolgarO, DeekenJ, ToKW, BatesSE: ABCG2: determining its relevance in clinical drug resistance.Cancer Metastasis Rev.26 , 39–57 (2007).
   PubMed Web of Science ®Google Scholar
• Lemos C , JansenG, PetersGJ: Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.Br. J. Cancer98 , 857–862 (2008).
   PubMed Web of Science ®Google Scholar
• Elkind NB , SzentpéteryZ, ApátiA et al.: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib).Cancer Res.65 , 1770–1777 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura Y , OkaM, SodaH et al.: Gefitinib (‘Iressa‘, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.Cancer Res.65 , 1541–1546 (2005).
   PubMed Web of Science ®Google Scholar
• Li J , CusatisG, BrahmerJ et al.: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.Cancer Biol. Ther.6 , 432–438 (2007).
   PubMed Web of Science ®Google Scholar
• Yanase K , TsukaharaS, AsadaS, IshikawaE, ImaiY, SugimotoY: Gefitinib reverses breast cancer resistance protein-mediated drug resistance.Mol. Cancer Ther.3 , 1119–1125 (2004).
   PubMed Web of Science ®Google Scholar
• Lemos C , KathmannI, GiovannettiE, CalhauC, JansenG, PetersGJ: Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.Br. J. Cancer100 , 1120–1127 (2009).
   PubMed Web of Science ®Google Scholar
• Usuda J , OhiraT, SugaY et al.: Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a ‘never-smoked‘ female patient with advanced non-small cell lung cancer.Lung Cancer58 , 296–299 (2007).
   PubMed Web of Science ®Google Scholar
• Robey RW , ToKK, PolgarO et al.: ABCG2: a perspective.Adv. Drug Deliv. Rev.61 , 3–13 (2009).
   PubMed Web of Science ®Google Scholar
• Imai Y , NakaneM, KageK et al.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.Mol. Cancer Ther.1 , 611–616 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo C , SuzukiH, ItodaM et al.: Functional analysis of SNPs variants of BCRP/ABCG2.Pharm. Res.21 , 1895–1903 (2004).
   PubMed Web of Science ®Google Scholar
• Kobayashi D , IeiriI, HirotaT et al.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.Drug Metab. Dispos.33 , 94–101 (2005).
   PubMed Web of Science ®Google Scholar
• Morisaki K , RobeyRW, Ozvegy-LaczkaC et al.: Single nucleotide polymorphisms modify the transporter activity of ABCG2.Cancer Chemother. Pharmacol.56 , 161–172 (2005).
   PubMed Web of Science ®Google Scholar
• Mizuarai S , AozasaN, KotaniH: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.Int. J. Cancer109 , 238–246 (2004).
   PubMed Web of Science ®Google Scholar
• Bram EE , IferganI, GrimbergM, LemkeK, SkladanowskiA, AssarafYG: C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.Biochem. Pharmacol.74 , 41–53 (2007).
   PubMed Web of Science ®Google Scholar
• Keskitalo JE , PasanenMK, NeuvonenPJ, NiemiM: Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.Pharmacogenomics10 , 1617–1624 (2009).
   PubMed Web of Science ®Google Scholar
• Sparreboom A , GelderblomH, MarshS et al.: Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.Clin. Pharmacol. Ther.76 , 38–44 (2004).
   PubMed Web of Science ®Google Scholar
• Cusatis G , GregorcV, LiJ et al.: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.J. Natl Cancer Inst.98 , 1739–1742 (2006).
   PubMed Web of Science ®Google Scholar
• Rudin CM , LiuW, DesaiA et al.: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.J. Clin. Oncol.26 , 1119–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Poonkuzhali B , LambaJ, StromS et al.: Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.Drug Metab. Dispos.36 , 780–795 (2008).
   PubMed Web of Science ®Google Scholar
• van Erp NP , EechouteK, van der Veldt AA et al.: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol.27 , 4406–4412 (2009).
   PubMed Web of Science ®Google Scholar
• Diestra JE , SchefferGL, CatalàI et al.: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.J. Pathol.198 , 213–219 (2002).
   PubMed Web of Science ®Google Scholar
• Zucali PA , RuizMG, GiovannettiE et al.: Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Ann. Oncol.19 , 1605–1612 (2008).
   PubMed Web of Science ®Google Scholar
• Maliepaard M , SchefferGL, FaneyteIF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.Cancer Res.61 , 3458–3464 (2001).
   PubMed Web of Science ®Google Scholar
• Lagendijk JH , MullinkH, van Diest PJ, Meijer GA, Meijer CJ: Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum. Pathol.29 , 491–497 (1998).
   PubMed Web of Science ®Google Scholar
• Tibaldi C , GiovannettiE, VasileE et al.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.Clin. Cancer Res.14 , 1797–1803 (2008).
   PubMed Web of Science ®Google Scholar
• Giovannetti E , ZucaliPA, PetersGJ et al.: Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.Mol. Cancer Ther.9 , 581–593 (2010).
   PubMed Web of Science ®Google Scholar
• Marsh S , MallonMA, GoodfellowP, McLeodHL: Concordance of pharmacogenetic markers in germline and colorectal tumor DNA.Pharmacogenomics6 , 873–877 (2005).
   PubMed Web of Science ®Google Scholar
• McWhinney SR , McLeodHL. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics10 , 489–493 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaR et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N. Engl. J. Med.350 , 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Sarkadi B , HomolyaL, SzakacsG, VaradiA: Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.Physiol Rev.86 , 1179–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Cusatis G , SparreboomA: Pharmacogenomic importance of ABCG2.Pharmacogenomics9 , 1005–1009 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R , SaltzL: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?J. Clin. Oncol.23 , 5235–5246 (2005).
   PubMed Web of Science ®Google Scholar
• Akasaka K , KaburagiT, YasudaS et al.: Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.Cancer Chemother. Pharmacol.66 , 691–698 (2010).
   PubMed Web of Science ®Google Scholar
• Urquhart BL , WareJA, TironaRG et al.: Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.Pharmacogenet. Genomics18 , 439–448 (2008).
   PubMed Web of Science ®Google Scholar
• Doyle LA , RossDD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).Oncogene22 , 7340–7358 (2003).
   PubMed Web of Science ®Google Scholar
• Eskens FA , MomCH, PlantingAS et al.: A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.Br. J. Cancer98 , 80–85 (2008).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Identification of EGFR-TKIs sensitivity or resistance markers in the tumor may help in optimal patient selection www.clinicaltrials.gov/ct2/show/NCT00831454
   Google Scholar
• CTEP protocol development www.ctep.cancer.gov/reporting/ctc.html
   Google Scholar
• ISTECH www.snp.istech.info/istech/board/login_form.jsp
   Google Scholar